Martin Auster is an equity research analyst with a focus on biotechnology. He currently leads the Smid cap biotechnology research effort at Credit Suisse. His professional background includes significant experience on both the sell-side and buy-side, having worked with hedge funds.

Auster's expertise extends to corporate biotechnology, where he has contributed to fundraising initiatives, including private financing and IPOs.